|Bid||211.85 x 900|
|Ask||212.15 x 800|
|Day's Range||209.94 - 215.20|
|52 Week Range||145.11 - 223.62|
|Beta (5Y Monthly)||0.85|
|PE Ratio (TTM)||34.46|
|Earnings Date||Apr 28, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||230.08|
ICON plc, (NASDAQ: ICLR) ICON plc, a global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, has won multiple categories in the annual CRO Leadership Awards.
Icon PLC (ICLR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of ICON PlcGlobal Credit Research - 14 Apr 2021Paris, April 14, 2021 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of ICON Plc and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review discussion held on 12 April 2021 in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. Since 1 January 2019, Moody's practice has been to issue a press release following each periodic review to announce its completion.This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.